A. Caldara

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Paolo Bossi, Rosalba Miceli, Laura D. Locati et al. · Annals of Oncology · 2017 · 80 citations

Medicine, Pathology, First-line Treatment +5

Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer

Annamaria Molino, Monica Giovannini, A. Auriemma et al. · Critical Reviews in Oncology/Hematology · 2006 · 68 citations

Surgical Oncology, Breast Oncology, Geriatrics +11

Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors

Orazio Caffo, Giovanni Pappagallo, S. Brugnara et al. · Urology · 2012 · 53 citations

Surgical Oncology, Urology, Genitourinary Cancer +10

Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma

Francesco Dionisi, Stefania Croci, Irene Giacomelli et al. · Acta Oncologica · 2019 · 49 citations · Full text

Surgical Oncology, Treatment Verification, Radiation Medicine +17